Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E J Clin Immunol. 2011 Aug; 31(4):623-31. Epub 2011 Apr 14. PMID: 21491095. Abstract CommentRecommendBookmarkWatch